The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure
Abstract
BACKGROUND: We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. METHODS: A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator. The primary composite end point was the time to death from or hospitalization for any cause. RESULTS: As compared with optimal pharmacologic therapy alone, cardiac-resynchronization therapy with a pacemaker decreased the risk of the primary end point (hazard ratio, 0.81; P=0.014), as did cardiac-resynchronization therapy with a pacemaker-defibrillator (hazard ratio, 0.80; P=0.01). The risk of the combined end point of death from or hospitalization for heart failure was reduced by 34 percent in the pacemaker group (P<0.002) and by 40 percent in the pacemaker-defibrillator group (P<0.001 for the comparison with the pharmacologic-therapy group). A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). CONCLUSIONS: In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While clinical improvements are generally achieved, six-month nonresponder rates have been reported to be as high as 32–43%11,13, which is partially attributed to anatomic constraints of lead positioning14.”
From Synchronized Biventricular Heart Pacing in a Closed-chest Porcine Model based on Wirelessly Powered Leadless Pacemakers (2020) · cites this paper as [13]
In the citing paper
“Device therapies (implantable cardioverter defibrillator [ICD], cardiac resynchronization therapy [CRT], and CRT with an implantable defibrillator [CRT-D]) have similar efficacies and risks in patients with HFrEF with or without diabetes.[522][523][524][525]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [524]
Citations
Cites
Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Brown, M. W., & Andrews, M. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013474 · Cited by 6,902
Cardiac Resynchronization in Chronic Heart Failure
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013168 · Cited by 4,648
CARDIAC RESYNCHRONIZATION IN CHRONIC HEART FAILURE
Braham, W. I. T. A., Isher, W. E. G. F., Mith, L. S., Elurgio, D. A. B. D., Eon, A. N. R. L., Oh, E., Ocovic, D. U. Z. K., Acker, M. G., Lavell, L. C., Ayes, D. A. L. H., et al. (2002) · Cited by 3,808
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Self-citationDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Self-citationSt John Sutton, M. G., Plappert, T., Abraham, W. T., Smith, A. L., DeLurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Fisher, W. G., Ellestad, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065226.24159.e9 · Cited by 1,124
Auricchio, A., Stellbrink, C., Sack, S., Block, M., Vogt, J. Ü., Bakker, P., Huth, C., Schöndube, F., Wolfhard, U., Böcker, D., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01895-8 · Cited by 1,026
Linde, C., Leclercq, C., Rex, S., Garrigue, S., Lavergne, T., Cazeau, S., McKenna, W., Fitzgerald, M., Deharo, J.-C., Alonso, C., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01932-0 · Cited by 973
Baldasseroni, S., Opasich, C., Gorini, M., Lucci, D., Marchionni, N., Marini, M., Campana, C., Perini, G., Deorsola, A., Masotti, G., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.121264 · Cited by 800
Cited by
Items 1,001–1,014 of 1,014
Hoppe, U. C., Freemantle, N., Cleland, J. G. F., Marijianowski, M., & Erdmann, E. (2007) · Diabetes Care · doi:10.2337/dc06-2035 · Cited by 43
Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1867 · Cited by 41
Self-citationLandolina, M., Gasparini, M., Lunati, M., Santini, M., Rordorf, R., Vincenti, A., Diotallevi, P., Montenero, A. S., Bonanno, C., de Santo, T., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.011 · Cited by 39
Hess, P. L., Jackson, K. P., Hasselblad, V., & Al-Khatib, S. M. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0330-6 · Cited by 38
Kiuchi, M. G., Ho, J. K., Nolde, J. M., Gavidia, L. M. L., Carnagarin, R., Matthews, V. B., & Schlaich, M. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01546 · Cited by 36
Epstein, A. E., Baessler, C. A., Curtis, A. B., Estes, N. A. M., Gersh, B. J., Grubb, B., & Mitchell, L. B. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.01.015 · Cited by 34
Johansson, I., & Strömberg, A. (2010) · Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e3181e0f881 · Cited by 34
Dilated Cardiomyopathy: From Genetics to Clinical Management
(2019) · doi:10.1007/978-3-030-13864-6 · Cited by 32
Carson, P., Fiuzat, M., O'Connor, C., Anand, I., Plehn, J., Lindenfeld, J. A., Silver, M., White, M., Miller, A., Davis, G., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.004 · Cited by 31
Self-citationRuwald, M. H., Zareba, W., Jons, C., Zhang, C., Ruwald, A.-C. H., Olshansky, B., McNitt, S., Bloch Thomsen, P. E., Shoda, M., Merkely, B., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002472 · Cited by 30
Siddiqui, W. J., Aggarwal, S., Rafique, M., Singh, S., Kutalek, S., & Eisen, H. J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9671-6 · Cited by 16
“3b), but there were only two studies [16, 26] which had reported these data.”
BackgroundMethodCzech Society of Cardiology Guidelines for the Diagnosis and Treatment of Chronic Heart Failure 2011
Špinar, J., Vítovec, J., Hradec, J., Málek, I., Meluzín, J., Špinarová, L., Hošková, L., Hegarová, M., Ludka, O., & Táborský, M. (2012) · Cor et Vasa · doi:10.1016/j.crvasa.2012.03.002 · Cited by 10
Strocchi, M., Wijesuriya, N., Elliott, M. K., Gillette, K., Neic, A., Mehta, V., Vigmond, E. J., Plank, G., Rinaldi, C. A., & Niederer, S. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1049214 · Cited by 8
“Over the next decade, the progress in image analysis, segmentation and simulation software will hopefully allow for larger virtual clinical trial including >1000 patients, consistent with large multi-centre trials (Bristow et al., 2004).”
Lyu, H., John, M., Burkland, D., Greet, B., Xi, Y., Sampaio, L. C., Taylor, D. A., Babakhani, A., & Razavi, M. (2018) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13738 · Cited by 5
“Despite great strides, contemporary CRT has a failure rate of 32% to 43% at 6 months.(17,19) While many reasons have been hypothesized for this inadequate response, recent focus has turned towards the anatomic constraints of lead positioning imposed by current lead designs.”
Background
Metadata
- Authors
- Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., DeVries, D. W., & Feldman, A. M.
- Affiliations
- University of Colorado Health (US)
- University of Southern California (US)
- Penn State Milton S. Hershey Medical Center (US)
- Bryan Health (US)
- Johns Hopkins Hospital (US)
- Veterans Health Administration (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Thomas Jefferson University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-05-20
- Volume
- 350
- Issue
- 21
- Pages
- 2140-2150
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2130907431
- Cited by
- 5,812
- References
- 22
- Citations by year
- 2026: 80 · 2025: 126 · 2024: 131 · 2023: 179 · 2022: 149 · 2021: 157 · 2020: 196 · 2019: 213 · 2018: 210 · 2017: 265 · 2016: 260 · 2015: 308 · 2014: 276 · 2013: 323 · 2012: 350
- FWCI
- 240.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Emergency Medicine › Cardiac Arrest and Resuscitation
- Keywords
- cardiac resynchronization therapy, implantable cardioverter-defibrillator, advanced chronic heart failure, intraventricular conduction delay, heart failure hospitalization, mortality, cardiomyopathy, QRS duration, pharmacotherapy
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Chronic Disease, Combined Modality Therapy, Diuretics, Female, Heart Failure, Hospitalization, Humans, Male, Pacemaker, Artificial, Risk, Spironolactone, Defibrillators, Implantable, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.